English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/212405
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


IL7RA rs6897932 polymorphism is associated with better CD4+ T-cell recovery in HIV infected patients starting combination antiretroviral therapy

AuthorsResino, Salvador; Navarrete-Muñoz, María A.; Blanco, Julià; Pacheco, Yolanda M. ; Castro, Iván; Berenguer, Juan; Santos, Jesús; Vera-Méndez, Francisco Jesús; Górgolas-Hernández-Mora, Miguel; Jiménez-Sousa, María A.; Benito, José Miguel; Rallón, Norma
Immune reconstitution
Issue Date2019
PublisherMultidisciplinary Digital Publishing Institute
CitationBiomolecules 9(6): 233 (2019)
AbstractInterleukin-7 receptor subunit alpha (IL7RA) rs6897932 polymorphism IS related to CD4+ recovery after combination antiretroviral therapy (cART), but no studies so far have analyzed its potential impact in patients with very low CD4+ T-cells count. We aimed to analyze the association between IL7RA rs6897932 polymorphism and CD4+ T-cells count restoration in HIV-infected patients starting combination antiretroviral therapy (cART) with CD4+ T-cells count <200 cells/mm3. We performed a retrospective study in 411 patients followed for 24 months with a DNA sample available for genotyping. The change in CD4+ T-cells count during the follow-up was considered as the primary outcome. The rs6897932 polymorphism had a minimum allele frequency (MAF) >20% and was in Hardy–Weinberg equilibrium (p = 0.550). Of 411 patients, 256 carried the CC genotype, while 155 had the CT/TT genotype. The CT/TT genotype was associated with a higher slope of CD4+ T-cells recovery (arithmetic mean ratio; AMR = 1.16; p = 0.016), higher CD4+ T-cells increase (AMR = 1.19; p = 0.004), and higher CD4+ T-cells count at the end of follow-up (AMR = 1.13; p = 0.006). Besides, rs6897932 CT/TT was related to a higher odds of having a value of CD4+ T-cells at the end of follow-up ≥500 CD4+ cells/mm3 (OR = 2.44; p = 0.006). After multiple testing correction (Benjamini–Hochberg), only the increase of ≥ 400 CD4+ cells/mm3 lost statistical significance (p = 0.052). IL7RA rs6897932 CT/TT genotype was related to a better CD4+ T-cells recovery and it could be used to improve the management of HIV-infected patients starting cART with CD4+ T-cells count <200 cells/mm3.
DescriptionThis article belongs to the Section Molecular Medicine.
Publisher version (URL)https://doi.org/10.3390/biom9060233
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
IL7RAtherap.pdf371,45 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.